PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect

Article Abstract:

The G-protein-coupled receptor, 'protein upregulated in macrophages by interferon-gamma (PUMA-G, human HM74) is a nicotinic acid (niacin) receptor and is expressed in adipose tissue. Research indicate that PUMA-G is involved in the anti-lipolytic and lipid-lowering effects of niacin as revealed by the niacin-induced decrease in freee fatty acid and triglyceride plasma levels are abrogated in the absence of PUMA-G.

Germany, Lipolysis, Nicotinic receptors, Antilipemic agents

---

Cholesterol esters and atherosclerosis - a game of ACAT and mouse

Article Abstract:

Research on acylCoA:cholesterol acyltransferase (ACAT2) in mice indicates that this cholesterol-modifying enzyme may be useful in preventing atherosclerosis. Findings show that by disrupting the gene that encodes ACAT2, researchers can reduce cholesterol absorption capacity and increase resistance to dietary hypercholesterolemia.

Prevention, Genetic aspects, Enzymes, Atherosclerosis, Esters, Enzyme therapy

---

Uncoupling diet and diabetes

Article Abstract:

Research demonstrates that a protein associated with the adipose tissue raises the metabolic rate of the body aiding in the reduction of obesity and enhancing insulin sensitivity in transgenic mice. Data suggest that pharmacological drugs designed to mimic this will be helpful in treating obesity and diabetes.

Diabetes, Diabetes mellitus, Striated muscle, Weight loss

Similar abstracts:

• Abstracts: Career development for women in academic medicine: multiple interventions in a department of medicine. Risk factors for 5-year mortality in older adults: the Cardiovascular Health Study
• Abstracts: Are managed care members satisfied? Manage authorizations to manage care. Protection for patients or providers?
• Abstracts: All our yesterdays. Back to front: Mention backsides and most people express revulsion or laugh nervously. Client and counsellor
• Abstracts: HIV-1 protease inhibitors: a review for clinicians. Acute human immunodeficiency virus type 1 infection. Evaluation of HIV-1 Immunogen, an Immunologic Modifier, Administered to Patients Infected With HIV Having 300 to 549 X [10.sup.6]/L CD4 Cell Counts: A Randomized Controlled Trial
• Abstracts: HPV vaccine moves into late stage trials. South African village prepares for first HIV vaccine trial... Hepatitis C virus and eliminating post-transfusion hepatitis

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.